Bellerophon Therapeutics Announces FDA Clears Initiation of Phase 3 Study for INOpulse® Inhaled Nitric Oxide Therapy to Treat COVID-19
May 11, 2020 08:30 ET
|
Bellerophon Therapeutics, Inc.
WARREN, N.J., May 11, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing...
Bellerophon Therapeutics to Participate in COVID-19 Panel at Maxim Group’s Infectious Disease Virtual Conference
May 04, 2020 08:30 ET
|
Bellerophon Therapeutics, Inc.
WARREN, N.J., May 04, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases,...
Bellerophon Therapeutics Submits Investigational New Drug Application to Study INOpulse® Inhaled Nitric Oxide Therapy for the Treatment of COVID-19
April 08, 2020 08:30 ET
|
Bellerophon Therapeutics, Inc.
WARREN, N.J., April 08, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary...
Bellerophon Provides Clinical Program Update and Reports Fourth Quarter and Full-Year 2019 Financial Results
April 06, 2020 10:23 ET
|
Bellerophon Therapeutics, Inc.
WARREN, N.J., April 06, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary...
Bellerophon Announces Closing of $15.3 Million Registered Direct Offering of Common Stock
April 01, 2020 13:06 ET
|
Bellerophon Therapeutics, Inc.
WARREN, N.J., April 01, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, closed its previously...
Bellerophon Therapeutics to Host Investor Call and Webcast Today on INOpulse® for the Treatment of COVID-19
March 31, 2020 08:30 ET
|
Bellerophon Therapeutics, Inc.
WARREN, N.J., March 31, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary...
Bellerophon Announces $15.3 Million Registered Direct Offering Priced At-the-Market
March 30, 2020 09:57 ET
|
Bellerophon Therapeutics, Inc.
WARREN, N.J., March 30, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced that it has...
Bellerophon Therapeutics Announces First Patient Treated with INOpulse® Inhaled Nitric Oxide Therapy for COVID-19
March 30, 2020 08:00 ET
|
Bellerophon Therapeutics, Inc.
WARREN, N.J., March 30, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary...
FDA Grants Bellerophon Emergency Expanded Access for INOpulse® for the Treatment of COVID-19 Virus
March 20, 2020 08:30 ET
|
Bellerophon Therapeutics, Inc.
WARREN, N.J., March 20, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced that the...
Bellerophon Announces Agreement with the FDA on its Planned Pivotal Phase 3 Study for the Treatment of Pulmonary Hypertension Associated with Pulmonary Fibrosis
March 10, 2020 08:30 ET
|
Bellerophon Therapeutics, Inc.
WARREN, N.J., March 10, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced the...